INMD is expected to report earnings to rise 35.20% to 33 cents per share on July 23
Q2'26
Est.
$0.34
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.04
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.06
The last earnings report on May 06 showed earnings per share of 25 cents, missing the estimate of 30 cents. With 521.57K shares outstanding, the current market capitalization sits at 767.37M.
A.I. Advisor
published General Information
General Information
a developer of minimally-invasive aesthetic medical products
A.I.dvisor indicates that over the last year, INMD has been loosely correlated with UTMD. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INMD jumps, then UTMD could also see price increases.
INMD in -1.55% downward trend, declining for three consecutive days on June 17, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where INMD declined for three days, in of 286 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
INMD moved below its 50-day moving average on May 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INMD crossed bearishly below the 50-day moving average on May 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.148) is normal, around the industry mean (10.753). P/E Ratio (9.785) is within average values for comparable stocks, (61.503). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.702). INMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (2.259) is also within normal values, averaging (23.787).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
